Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Amortizatization of Intangibles (2019 - 2025)

Allogene Therapeutics' Amortizatization of Intangibles history spans 7 years, with the latest figure at $923000.0 for Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 45.67% year-over-year to $923000.0; the TTM value through Sep 2025 reached $5.1 million, down 49.47%, while the annual FY2024 figure was $8.3 million, 22.6% up from the prior year.
  • Amortizatization of Intangibles for Q3 2025 was $923000.0 at Allogene Therapeutics, down from $1.2 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.3 million in Q4 2023 and bottomed at -$1.9 million in Q1 2021.
  • The 5-year median for Amortizatization of Intangibles is $1.1 million (2023), against an average of $610631.6.
  • The largest annual shift saw Amortizatization of Intangibles plummeted 1044.44% in 2021 before it skyrocketed 694.75% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$1.6 million in 2021, then soared by 271.58% to $2.7 million in 2022, then grew by 20.62% to $3.3 million in 2023, then plummeted by 49.95% to $1.7 million in 2024, then crashed by 44.09% to $923000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Amortizatization of Intangibles are $923000.0 (Q3 2025), $1.2 million (Q2 2025), and $1.3 million (Q1 2025).